Exicure Inc(XCUR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:05 AM ET (Korea 11/5 18:05)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.3 | Insider Own | 42.98% | Shs Outstand | 6.4M | Perf Week | -2.33% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.7M | Perf Month | -8.08% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.09% | Short Float | 1.15% | Perf Quarter | -26.46% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -2.16% | Short Ratio | 0.95 | Perf Half Y | -70.71% |
| Sales | 0.00B | P/B | 6.48 | EPS next 5Y | - | ROA | -54.98% | Short Interest | 0.04M | Perf YTD | -81.68% |
| Book/sh | 0.15 | P/C | 3.78 | EPS past 3/5Y | 34.5% 54.97% | ROE | -168.37% | 52W High | -89.53% ($9.48) | Perf Year | -76.53% |
| Cash/sh | 0.26 | P/FCF | - | Sales past 3/5Y | - | ROIC | -847.9% | 52W Low | 13.44% ($0.88) | Perf 3Y | -68.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.05% | Gross Margin | - | Volatility(W/M) | 12.5% 11.38% | Perf 5Y | -99.44% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.56 | EPS Q/Q | 57.6% | Profit Margin | - | RSI (14) | 42.15 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.56 | Sales Q/Q | - | SMA20 | -5.91% ($1.05) | Beta | 3.74 | Target Price | $10.33 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -15.79% ($1.18) | Rel Volume | 0.41 | Prev Close | $1.01 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -62.39% ($2.63) | Avg Volume(3M) | 0.04M | Price | $0.99 |
| IPO | 2018/5/22 | Option/Short | No/Yes | Trades | 111 | Volume | 18,519 | Change | -1.7% |
🧬 This micro-cap biotech developed gene-regulating and immunotherapies based on its proprietary SNA (Spherical Nucleic Acid) platform. It recently acquired GPC-100 (Burixafor), a multiple myeloma drug candidate, adding a clinical-stage pipeline and is currently in the process of restructuring as a clinical-stage company.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded less than usual. That is 41% of its average volume.
XCUR has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #530 of 597 in the industry
Based on market cap of $7M.
FAQ
What kind of company is XCUR?
XCUR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XCUR?
The market cap of XCUR is approximately $7M, ranking 5,550 within its sector.
What is the 52-week high and low for XCUR?
XCUR has recorded a 52-week high of $9.48 and a low of $0.88.
